Psychedelic drugs, including LSD, were popular in the 1970s and have been gaining popularity over the past decade, with reports of young professionals claiming to regularly take small non-hallucinogenic micro-doses of LSD to boost their productivity and creativity and to increase their empathy.
Microdosing is the act of consuming sub-perceptual (unnoticeable) amounts of a psychedelic substance. Many individuals who have integrated microdosing LSD into their weekly routine report higher levels of creativity, more energy, increased focus, and improved relational skills, as well as reduced symptoms of depression. Some enthusiasts also report that microdosing LSD has helped them heighten their spiritual awareness and enhance their senses.
For several decades, psychedelics have been uniformly outlawed, with [...]
Psychedelic medicine biotech firm MindMed has announced it has begun a study for a “neutralizer” technology that could shorten and stop the effects of an LSD trip during therapy, paving the way for an “emergency shut-off switch” for psychedelic-assisted therapy.
MindMed has several therapies based on lysergic acid diethylamide (LSD) in the phase 2 for treatment of anxiety and cluster headaches, which would be used as an aid during therapy sessions.
MindMed is one of those companies. The Toronto-based firm is led by JR Rahn, a former Uber executive whose cocaine addiction led him to try psychedelics as a treatment—an experience he credits with saving his life. Rahn believes drugs like LSD could hold the key to helping the millions of people who have been driven to despair by the pandemic.
The psychedelic state induced by LSD appears to weaken the association between anatomical brain structure and functional connectivity, according to new research published in the journal NeuroImage.